|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
*
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
IT1289608B1
(it)
*
|
1997-02-05 |
1998-10-15 |
Angelini Ricerche Spa |
Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
|
|
NZ520472A
(en)
*
|
2000-02-03 |
2004-03-26 |
Lennart Hammarstrom |
Ruminant MHC class I-like Fc receptors
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
PT1355919E
(pt)
|
2000-12-12 |
2011-03-02 |
Medimmune Llc |
Moléculas com semivida longa, composições que as contêm e suas utilizações
|
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
|
JP2005503116A
(ja)
|
2001-02-09 |
2005-02-03 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
|
|
CA2444632A1
(en)
|
2001-04-13 |
2002-10-24 |
Human Genome Sciences, Inc. |
Vascular endothelial growth factor 2
|
|
AU2002254753C1
(en)
*
|
2001-05-01 |
2008-09-18 |
The Regents Of The University Of California |
Fusion molecules and methods for treatment of immune diseases
|
|
US7265208B2
(en)
|
2001-05-01 |
2007-09-04 |
The Regents Of The University Of California |
Fusion molecules and treatment of IgE-mediated allergic diseases
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
AU2002316574B2
(en)
*
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
|
AT502293B1
(de)
*
|
2002-05-15 |
2008-03-15 |
Igeneon Krebs Immuntherapie |
Immunogener, monoklonaler antikörper
|
|
AU2003232081B2
(en)
*
|
2002-07-03 |
2009-02-05 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US20060248617A1
(en)
|
2002-08-30 |
2006-11-02 |
Japan Science And Technology Corporation |
Method of targeted gene disruption, genome of hyperthermostable bacterium and genome chip using the same
|
|
EP1585815A4
(en)
|
2003-01-21 |
2006-02-22 |
Bristol Myers Squibb Co |
A NEW ACYL-COENZYME A, MONOCLYLGLYCERIN ACYLTRANSFERASE-3 (MGAT3), CODING POLYNUCLEOTIDE, AND USES THEREOF
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
JP4764818B2
(ja)
|
2003-04-11 |
2011-09-07 |
メディミューン，エルエルシー |
組換えｉｌ−９抗体およびその使用
|
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
|
PT1624891E
(pt)
|
2003-05-06 |
2010-01-05 |
Syntonix Pharmaceuticals Inc |
Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
|
|
AU2016244273B2
(en)
*
|
2003-05-06 |
2018-10-18 |
Bioverativ Therapeutics Inc. |
Immunoglobulin Chimeric Monomer-Dimer Hybrids
|
|
TWI353991B
(en)
*
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
AU2012200470B2
(en)
*
|
2003-05-06 |
2014-12-18 |
Bioverativ Therapeutics Inc. |
Immunoglobulin Chimeric Monomer-Dimer Hybrids
|
|
AU2003232751A1
(en)
*
|
2003-05-12 |
2004-11-26 |
Tolerogen, Ltd. |
Immunoglobulin conjugates of autoantigens and their use in the prevention of disease
|
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
DK1817340T3
(da)
|
2004-11-12 |
2012-08-13 |
Xencor Inc |
Fc-varianter med ændret binding til fcrn
|
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
CN102321174B
(zh)
|
2005-05-06 |
2013-10-16 |
津莫吉尼蒂克斯公司 |
Il-31单克隆抗体及使用方法
|
|
US7482124B2
(en)
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
WO2007044616A2
(en)
|
2005-10-06 |
2007-04-19 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
EP2027291A2
(en)
|
2006-04-27 |
2009-02-25 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
ES2439994T3
(es)
|
2006-08-28 |
2014-01-27 |
Kyowa Hakko Kirin Co., Ltd. |
Anticuerpos antagonistas monoclonales humanos específicos de LIGHT humano
|
|
DK2594586T3
(en)
|
2006-09-01 |
2014-11-17 |
Zymogenetics Inc |
Monoclonal il-31 antibodies and methods of use thereof
|
|
EP2061904A2
(en)
|
2006-09-06 |
2009-05-27 |
Ortho-McNeil Pharmaceutical, Inc. |
Biomarkers for assessing response to c-met treatment
|
|
WO2008036688A2
(en)
|
2006-09-18 |
2008-03-27 |
Xencor, Inc. |
Optimized antibodies that target hm1.24
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
EP2796466B1
(en)
|
2007-12-07 |
2017-11-22 |
ZymoGenetics, Inc. |
Humanized antibody molecules specific for IL-31
|
|
RU2529951C2
(ru)
|
2007-12-26 |
2014-10-10 |
Ксенкор, Инк. |
ВАРИАНТЫ Fc С ИЗМЕНЕННЫМ СВЯЗЫВАНИЕМ C FcRn
|
|
US12492253B1
(en)
|
2008-02-25 |
2025-12-09 |
Xencor, Inc. |
Anti-human C5 antibodies
|
|
EP2260102A1
(en)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by down-regulating frizzled-4 and/or frizzled-1
|
|
US8150140B2
(en)
|
2008-12-22 |
2012-04-03 |
Ngr Inc. |
System and method for a semiconductor lithographic process control using statistical information in defect identification
|
|
US20110311521A1
(en)
|
2009-03-06 |
2011-12-22 |
Pico Caroni |
Novel therapy for anxiety
|
|
EP2241323A1
(en)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W and brain cancers
|
|
WO2010141329A1
(en)
|
2009-06-01 |
2010-12-09 |
Medimmune, Llc |
Molecules with extended half-lives and uses thereof
|
|
PL2464664T3
(pl)
|
2009-08-13 |
2016-02-29 |
Crucell Holland Bv |
Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
|
|
ES2666152T3
(es)
|
2009-08-13 |
2018-05-03 |
The Johns Hopkins University |
Métodos de modulación de la función inmunitaria con anticuerpos anti-B7-H7CR
|
|
EP2292266A1
(en)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Treating cancer by modulating copine III
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
WO2011036118A1
(en)
|
2009-09-22 |
2011-03-31 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mex-3
|
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
|
WO2011131611A1
(en)
|
2010-04-19 |
2011-10-27 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Modulating xrn1
|
|
WO2011154485A1
(en)
|
2010-06-10 |
2011-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Treating cancer by modulating mammalian sterile 20-like kinase 3
|
|
PH12012502244A1
(en)
|
2010-07-09 |
2016-09-30 |
Crucell Holland Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
|
UA126265C2
(uk)
|
2010-07-09 |
2022-09-14 |
Байовератів Терапьютікс Інк. |
Поліпептид фактора іх і спосіб його застосування
|
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
|
WO2012038744A2
(en)
|
2010-09-22 |
2012-03-29 |
Genome Research Limited |
Detecting mutations
|
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
WO2012168259A1
(en)
|
2011-06-06 |
2012-12-13 |
Novartis Forschungsstiftung, Zweigniederlassung |
Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
|
|
CN104039830A
(zh)
|
2011-11-04 |
2014-09-10 |
诺华股份有限公司 |
低密度脂蛋白相关蛋白6(lrp6)-半寿期延长物构建体
|
|
US20140314787A1
(en)
|
2011-11-08 |
2014-10-23 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute |
Treatment for neurodegenerative diseases
|
|
EP2776838A1
(en)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Early diagnostic of neurodegenerative diseases
|
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
|
WO2013144240A1
(en)
|
2012-03-29 |
2013-10-03 |
Friedrich Miescher Institute For Biomedical Research |
Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer
|
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
|
CN116574185A
(zh)
|
2012-07-25 |
2023-08-11 |
塞尔德克斯医疗公司 |
抗kit抗体及其用途
|
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
SG11201509982UA
(https=)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
EP3030902B1
(en)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
New screening method for the treatment friedreich's ataxia
|
|
KR102313341B1
(ko)
|
2013-08-26 |
2021-10-18 |
바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 |
시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
|
|
CN112142843B
(zh)
|
2013-12-24 |
2024-10-18 |
阿尔金克斯有限公司 |
FcRn拮抗剂及使用方法
|
|
PT3097122T
(pt)
|
2014-01-24 |
2020-07-21 |
Ngm Biopharmaceuticals Inc |
Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US8961992B1
(en)
|
2014-04-02 |
2015-02-24 |
Tunitas Therapeutics, Inc. |
Epsigam fusion protein
|
|
CA2947605A1
(en)
|
2014-05-13 |
2015-11-19 |
Bioatla, Llc |
Conditionally active biological proteins
|
|
EP3142700B1
(en)
|
2014-05-16 |
2021-03-03 |
Medimmune, LLC |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
|
DK3154583T3
(da)
|
2014-06-04 |
2021-03-22 |
Biontech Res And Development Inc |
Humane monoklonale antistoffer mod gangliosid gd2
|
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
|
WO2016036916A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
US20170298360A1
(en)
|
2014-09-24 |
2017-10-19 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
AU2016222830B2
(en)
|
2015-02-24 |
2021-02-25 |
Bioatla Llc |
Conditionally active biological proteins
|
|
MX2017011194A
(es)
|
2015-03-03 |
2018-04-10 |
Kymab Ltd |
Anticuerpos, usos y métodos.
|
|
JP7118884B2
(ja)
*
|
2015-07-17 |
2022-08-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Ｆｃ結合抗原の粘膜ワクチン接種によって免疫寛容を誘導するための方法及び医薬組成物
|
|
CA2995838A1
(en)
|
2015-08-19 |
2017-02-23 |
Rutgers, The State University Of New Jersey |
Novel methods of generating antibodies
|
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
|
WO2017078839A1
(en)
|
2015-11-02 |
2017-05-11 |
Bioatla, Llc |
Conditionally active polypeptides
|
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
KR102637960B1
(ko)
|
2017-04-22 |
2024-02-21 |
이뮤노믹 쎄라퓨틱스, 인크. |
개선된 lamp 구축물
|
|
US12358962B2
(en)
|
2017-05-02 |
2025-07-15 |
Immunomic Therapeutics, Inc. |
Lamp constructs comprising cancer antigens
|
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
|
US12240875B2
(en)
|
2017-12-08 |
2025-03-04 |
argenx BV |
Use of FCRN antagonists for treatment of generalized myasthenia gravis
|
|
CA3101462A1
(en)
|
2018-06-08 |
2019-12-12 |
Argenx Bvba |
Compositions and methods for treating immune thrombocytopenia
|
|
KR102767692B1
(ko)
|
2018-07-20 |
2025-02-17 |
피에르 파브르 메디카먼트 |
Vista의 수용체
|
|
SG11202102851XA
(en)
|
2018-09-27 |
2021-04-29 |
Celgene Corp |
SIRPa BINDING PROTEINS AND METHODS OF USE THEREOF
|
|
CN114126647A
(zh)
|
2019-06-07 |
2022-03-01 |
阿尔金克斯有限公司 |
适用于皮下施用的FcRn抑制剂的药物制剂
|
|
EP4045528A1
(en)
|
2019-10-18 |
2022-08-24 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs comprising cancer antigens
|
|
BR112022013554A2
(pt)
|
2020-01-08 |
2022-09-06 |
argenx BV |
Métodos para tratar distúrbios do pênfigo
|
|
JP7846667B2
(ja)
|
2020-07-16 |
2026-04-15 |
レジェンド バイオテック アイルランド リミテッド |
Ｃｄ２０結合分子及びその使用
|
|
EP4188960A4
(en)
|
2020-08-03 |
2024-09-11 |
Janssen Biotech, Inc. |
MATERIALS AND METHODS FOR MULTIDIRECTIONAL BIOTRANSPORTATION IN VIROTHERAPEUTIC PRODUCTS
|
|
CA3192526A1
(en)
|
2020-09-04 |
2022-03-10 |
Rutgers, The State University Of New Jersey |
Sars-cov-2 vaccines and antibodies
|
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
|
CN117157318A
(zh)
|
2020-12-30 |
2023-12-01 |
免疫治疗有限公司 |
抗hvem抗体
|
|
JP2024502832A
(ja)
|
2020-12-31 |
2024-01-23 |
アラマー バイオサイエンシーズ， インコーポレイテッド |
高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
|
|
CA3209052A1
(en)
|
2021-02-19 |
2022-08-25 |
Rafael Cristian CASELLAS |
Single domain antibodies that neutralize sars-cov-2
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
CA3258000A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
|
|
CA3262035A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
BIOLOGICALLY ENGINEERED IMPROVED MATERIAL AND PAIRING METHODS FOR VARIABLE ANTIGEN-BINDING REGIONS
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
WO2025104604A1
(en)
|
2023-11-14 |
2025-05-22 |
Janssen Pharmaceuticals, Inc. |
Anti-respiratory syncytial virus antibodies and uses thereof
|
|
WO2025155971A1
(en)
|
2024-01-19 |
2025-07-24 |
Immunomic Therapeutics, Inc |
Anti-activin receptor 1c (alk-7) receptor antibodies
|